Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
First-in-human trial initiations feature Interius, Umoja and Vironexis.